US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NOMAD Power Solutions

4.84

-0.0300-0.62%

Post-market: 4.82-0.0200-0.41%19:58 EDT

Volume:190.60K

Turnover:910.80K

Market Cap:98.63M

PE:-4.21

High:5.00

Open:4.99

Low:4.60

Close:4.87

52wk High:8.38

52wk Low:2.36

Shares:20.38M

Float Shares:17.44M

Volume Ratio:0.53

T/O Rate:1.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.1500

EPS(LYR):-1.2600

ROE:--

ROA:--

PB:--

PE(LYR):-3.84

Loading ...

Overview Company News Filings

Company Profile

Company Name:

NOMAD Power Solutions

Exchange:

NASDAQ

Establishment Date:

2020

Employees:

- -

Office Location:

433 Plaza Real,Suite 275,Boca Raton,Florida,United States

Website:

http://www.lixte.com

Zip Code:

33432

Phone:

Fax:

- -

Introduction:

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

Directors

Name

Position

Geordan G. Pursglove

Chairman of the Board and Chief Executive Officer and Director and President

Guy Primus

Director

Jason D. Sawyer

Director

Lourdes Felix

Director

Michael Holloway

Director

Stuart D. Porter

Director

Shareholders

Name

Position

Geordan G. Pursglove

Chairman of the Board and Chief Executive Officer and Director and President

Peter Stazzone

Chief Financial Officer

Bas van der Baan

Chief Scientific Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NMAD/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NMAD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NMAD\",,,,,undefined,":{"symbol":"NMAD","market":"US","secType":"STK","nameCN":"NOMAD Power Solutions","latestPrice":4.84,"timestamp":1784923200000,"preClose":4.87,"halted":0,"volume":190601,"hourTrading":{"tag":"盘后","latestPrice":4.82,"preClose":4.84,"latestTime":"19:58 EDT","volume":12158,"amount":59558.332,"timestamp":1784937513213,"change":-0.02,"changeRate":-0.004132,"amplitude":0.039256},"delay":0,"changeRate":-0.0061601642710472785,"floatShares":17436409,"shares":20378500,"eps":-1.15,"marketStatus":"Market Closed","change":-0.03,"latestTime":"07-24 16:00:00 EDT","open":4.99,"high":5,"low":4.6,"amount":910796.1607687,"amplitude":0.082136,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.15,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"listingDate":1606280400000,"exchange":"NASDAQ","adjPreClose":4.87,"preHourTrading":{"tag":"盘前","latestPrice":4.99,"preClose":4.87,"latestTime":"09:29 EDT","volume":1200,"amount":5848.4796,"timestamp":1784899799999,"change":0.12,"changeRate":0.024641,"amplitude":0.057495},"postHourTrading":{"tag":"盘后","latestPrice":4.82,"preClose":4.84,"latestTime":"19:58 EDT","volume":12158,"amount":59558.332,"timestamp":1784937513213,"change":-0.02,"changeRate":-0.004132,"amplitude":0.039256},"volumeRatio":0.5327843427060129},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NMAD\",,,,,undefined,":{"symbol":"NMAD","floatShares":17436409,"roa":"--","roe":"--","lyrEps":-1.259999,"volumeRatio":0.5327843427060129,"shares":20378500,"dividePrice":0,"high":5,"amplitude":0.082136,"preClose":4.87,"low":4.6,"week52Low":2.36,"pbRate":"--","week52High":8.3773,"institutionHeld":0,"latestPrice":4.84,"eps":-1.15,"divideRate":0,"volume":190601,"delay":0,"ttmEps":-1.15,"open":4.99,"prevYearClose":3.93,"prevWeekClose":5.79,"prevMonthClose":7.42,"prevQuarterClose":7.42,"fiveDayClose":5.79,"twentyDayClose":6.65,"sixtyDayClose":3.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NMAD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-07-06","symbol":"NMAD","reason":null,"defaultRemindTime":1783344600000,"announcedDate":"2026-07-02","type":"delisting","dateTimestamp":1783310400000},{"market":"US","date":"2026-05-14","symbol":"NMAD","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-0.18},{"market":"US","date":"2026-03-31","symbol":"NMAD","fiscalQuarterEnding":"2025/12","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1774929600000,"reportTimeType":"","actualEps":-0.33},{"market":"US","date":"2025-11-12","symbol":"NMAD","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-0.33},{"market":"US","date":"2025-05-12","symbol":"NMAD","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":-0.29}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NMAD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NMAD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1853090516,"yearFounded":2020,"address":"433 Plaza Real,Suite 275,Boca Raton,Florida,United States","zipCode":"33432","officePhone":"802 555 0123"},"stockCompanyDetail":{"websiteUrl":"http://www.lixte.com","stockEarnings":[{"period":"1week","weight":-0.1641},{"period":"1month","weight":-0.2955},{"period":"3month","weight":0.3046},{"period":"6month","weight":0.4535},{"period":"1year","weight":0.1282},{"period":"ytd","weight":0.2316}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.153774},{"month":2,"riseRate":0.625,"avgChangeRate":0.06495},{"month":3,"riseRate":0.5,"avgChangeRate":-0.03366},{"month":4,"riseRate":0.375,"avgChangeRate":-0.074412},{"month":5,"riseRate":0.444444,"avgChangeRate":0.082784},{"month":6,"riseRate":0.555556,"avgChangeRate":0.048502},{"month":7,"riseRate":0.555556,"avgChangeRate":0.317781},{"month":8,"riseRate":0.5,"avgChangeRate":0.097631},{"month":9,"riseRate":0.375,"avgChangeRate":0.00973},{"month":10,"riseRate":0.375,"avgChangeRate":-0.019298},{"month":11,"riseRate":0.375,"avgChangeRate":-0.035386},{"month":12,"riseRate":0.25,"avgChangeRate":-0.145393}],"exchange":"NASDAQ","name":"NOMAD Power Solutions","nameEN":"NOMAD Power Solutions"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"NMAD\",market:\"US\",,,undefined,":{"directors":[{"name":"Geordan G. Pursglove","position":"Chairman of the Board and Chief Executive Officer and Director and President"},{"name":"Guy Primus","position":"Director"},{"name":"Jason D. Sawyer","position":"Director"},{"name":"Lourdes Felix","position":"Director"},{"name":"Michael Holloway","position":"Director"},{"name":"Stuart D. Porter","position":"Director"}],"executives":[{"name":"Geordan G. Pursglove","position":"Chairman of the Board and Chief Executive Officer and Director and President"},{"name":"Peter Stazzone","position":"Chief Financial Officer"},{"name":"Bas van der Baan","position":"Chief Scientific Officer"}]}}}